{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15092", "batch_size": 260, "batch_pos": 165, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment is a factual report of actions, not using high-potency framing.", "method": "llm_batch", "batch_id": "batch_2_16312", "batch_size": 260, "batch_pos": 136, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment describes actions/plans ('developing or about to test'), not a moderate verb paired with realised impact.", "method": "llm_batch", "batch_id": "batch_3_17744", "batch_size": 260, "batch_pos": 69, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_16284", "batch_size": 260, "batch_pos": 56, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports vaccine development efforts but lacks explicit calming language about current safety.", "method": "llm_batch", "batch_id": "batch_5_11376", "batch_size": 260, "batch_pos": 52, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_7316", "batch_size": 260, "batch_pos": 18, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation about risk, cases, or capability.", "method": "llm_batch", "batch_id": "batch_7_17788", "batch_size": 260, "batch_pos": 258, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes development capability/preparedness activity: 'they are already developing or about to test sample human vaccines'.", "method": "llm_batch", "batch_id": "batch_8_17448", "batch_size": 260, "batch_pos": 95, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
